Phase II Study of Alimta (Pemetrexed) Treatment of Advanced Thymoma and Thymic Carcinoma
Thymoma, Thymic Carcinoma
About this trial
This is an interventional treatment trial for Thymoma focused on measuring Thymoma, Thymic Carcinoma
Eligibility Criteria
Inclusion Criteria: Histologically confirmed invasive, recurrent or metastatic thymoma or thymic carcinoma not amenable to potentially curative therapy by surgery. Original biopsy of tumor is sufficient for diagnoses unless otherwise clinically indicated. Patients must have measurable disease with at least one bidimensional measurable lesion. Any scans or x-rays used to document measurable disease must be obtained with 6 weeks prior to registration. Patients may have had prior chemotherapy for metastatic disease Adequate organ function as defined by: bili </=1.5; calc. crt clr of >/=45; hematologic-granulocytes >/=1500 & plt >/=100K. Patients who are receiving a stable dose of corticosteroids for myasthenia gravis are eligible. ECOG performance status of 0 or 1 Exclusion Criteria: Acute intercurrent infection or complications pregnancy or lactating patients Inability to interrupt aspirin or other nonsteroidal anti-inflammatory agents for a 5-day period (8-day period for long-acting agents. Presence of clinically relevant third-space fluid collections that cannot be controlled by a procedure
Sites / Locations
- Indiana University Cancer Center
Arms of the Study
Arm 1
Experimental
Pemetrexed
Pemetrexed infusion once every 21 days (one cycle).